Floatz logo

Wild-Type Reovirus

Pancreatic Acinar Cell Carcinoma

National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Pancreatic Acinar Cell Carcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Yale University
Phase 2BBB
Eloxatin
Yale University
Phase 2BBB
Irinotecan
Artios Pharma Ltd
Phase 2BB
Metformin
Case Comprehensive Cancer Center
Phase 2BB
Bryostatin 1
National Cancer Institute (NCI)
Phase 2B

View all 34 →

Same molecule, other indications

Wild-Type Reovirus is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →
exocrine pancreatic carcinomaDormant
B
Indicative ·
57 / 100
View asset →
melanomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →